|
1
|
Sathiyasekar AC, Chandrasekar P, Pakash A,
Kumar KUG and Jaishlal MS: Overview of immunology of oral squamous
cell carcinoma. J Pharm Bioallied Sci. 8(Suppl 1): S8–S12.
2016.PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai
HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT and Chen CJ: High
PD-L1 expression correlates with metastasis and poor prognosis in
oral squamous cell carcinoma. PLoS One. 10:e01426562015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferris RL: Immunology and immunotherapy of
head and neck cancer. J Clin Oncol. 33:3293–3304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu W, Lu L, Feng Y, Chen J, Li Y, Kong X,
Chen S, Li X, Chen Q and Zhang P: Inflammation promotes oral
squamous carcinoma immune evasion via induced programmed death
ligand-1 surface expression. Oncol Lett. 5:1519–1526. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ritprajak P and Azuma M: Intrinsic and
extrinsic control of expression of the immunoregulatory molecule
PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol.
51:221–228. 2015. View Article : Google Scholar
|
|
7
|
Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X
and Li L: IFN-γ-mediated inhibition of lung cancer correlates with
PD-L1 expression and is regulated by PI3K-AKT signaling. Int J
Cancer. 143:931–943. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moon JW, Kong SK, Kim BS, Kim HJ, Lim H,
Noh K, Kim Y, Choi JW, Lee JH and Kim YS: IFNγ induces PD-L1
overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive
gastric carcinoma. Sci Rep. 7:178102017. View Article : Google Scholar
|
|
9
|
Bu L, Yu G, Wu L, Mao L, Deng WW, Liu JF,
Kulkarni AB, Zhang WF, Zhang L and Sun ZJ: STAT3 induces
immunosuppression by upregulating PD-1/PD-L1 in HNSCC. J Dent Res.
96:1027–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roy A, Ye J, Deng F and Wang QJ: Protein
kinase D signaling in cancer: A friend or foe? Biochim Biophys Acta
Rev Cancer. 1868:283–294. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y
and Zhang P: Interferon-γ-induced PD-L1 surface expression on human
oral squamous carcinoma via PKD2 signal pathway. Immunobiology.
217:385–393. 2012. View Article : Google Scholar
|
|
12
|
LaValle CR, George KM, Sharlow ER, Lazo
JS, Wipf P and Wang QJ: Protein kinase D as a potential new target
for cancer therapy. Biochim Biophys Acta. 1806:183–192.
2010.PubMed/NCBI
|
|
13
|
Evans IM and Zachary IC: Protein kinase D
in vascular biology and angiogenesis. IUBMB Life. 63:258–263. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang T, Braun U and Leitges M: PKD3
deficiency causes alterations in microtubule dynamics during the
cell cycle. Cell Cycle. 15:1844–1854. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Durand N, Borges S and Storz P: Protein
kinase D enzymes as regulators of EMT and cancer cell invasion. J
Clin Med. 5:E202016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baker J, Falconer AM, Wilkinson DJ,
Europe-Finner GN, Litherland GJ and Rowan AD: Protein kinase D3
modulates MMP1 and MMP13 expression in human chondrocytes. PLoS
One. 13:pp. e01958642018, View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rozengurt E, Rey O and Waldron RT: Protein
kinase D signaling. J Biol Chem. 280:pp. 13205–13208. 2005,
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Deng F, Singh SV and Wang QJ:
Protein kinase D3 (PKD3) contributes to prostate cancer cell growth
and survival through a PKCε/PKD3 pathway downstream of Akt and ERK
1/2. Cancer Res. 68:3844–3853. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zou Z, Zeng F, Xu W, et al: PKD2 and PKD3
Promote Prostate Cancer Cell Invasion by Modulating NF-κB- And
HDAC1-mediated Expression and Activation of uPA. J Cell Sci.
125:4800–4811. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J, Wang CM, Zhang P, Wang X, Chen J,
Yang J, Lu W, Zhou W, Yuan W and Feng Y: Expression of programmed
death 1 ligand 1 on periodontal tissue cells as a possible
protective feedback mechanism against periodontal tissue
destruction. Mol Med Rep. 13:2423–2430. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin W, Choe WH, Hiasa Y, Kamegaya Y,
Blackard JT, Schmidt EV and Chung RT: Hepatitis C virus expression
suppresses interferon signaling by degrading STAT1.
Gastroenterology. 128:1034–1041. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Konnikova L, Kotecki M, Kruger MM and
Cochran BH: Knockdown of STAT3 expression by RNAi induces apoptosis
in astrocytoma cells. BMC Cancer. 3:232003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu W and Steinberg SF: Phos-tag SDS-PAGE
resolves agonist-and isoform-specific activation patterns for PKD2
and PKD3 in cardiomyocytes and cardiac fibroblasts. J Mol Cell
Cardiol. 99:14–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin C, Cao W, Ren Z, Tang Y, Zhang C, Yang
R, Chen Y, Liu Z, Peng C, Wang L, et al: GDNF secreted by nerves
enhances PD-L1 expression via JAK2-STAT1 signaling activation in
HNSCC. Oncoimmunology. 6:e13538602017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Concha-Benavente F, Srivastava RM, Trivedi
S, Lei Y, Chandran U, Seethala RR, Freeman GJ and Ferris RL:
Identification of the cell-intrinsic and-extrinsic pathways
downstream of EGFR and IFNγ that induce PD-L1 expression in head
and neck cancer. Cancer Res. 76:1031–1043. 2016. View Article : Google Scholar
|
|
26
|
Mann J, Hoesli R, Michmerhuizen N,
Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, Jawad N,
Mierzwa M, Shuman AG, et al: Surveilling the potential for
precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC. J
Cancer. 8:332–344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang H, Xu M, Chi X, Yan Q, Wang Y, Xu W,
Zhuang K, Li A and Liu S: Higher PKD3 expression in hepatocellular
carcinoma (HCC) tissues predicts poorer prognosis for HCC patients.
Clin Res Hepatol Gastroenterol. 41:554–563. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huck B, Duss S, Hausser A and Olayioye MA:
Elevated protein kinase D3 (PKD3) expression supports proliferation
of triple-negative breast cancer cells and contributes to
mTORC1-S6K1 pathway activation. J Biol Chem. 289:3138–3147. 2014.
View Article : Google Scholar :
|
|
29
|
Mimura K, The JL, Okayama H, Shiraishi K,
Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, et al:
PD-L1 expression is mainly regulated by interferon gamma associated
with JAK-STAT pathway in gastric cancer. Cancer Sci. 109:43–53.
2018. View Article : Google Scholar
|
|
30
|
Vassilakopoulou M, Avgeris M, Velcheti V,
Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK,
Giotakis AI, Scorilas A, et al: Evaluation of PD-L1 expression and
associated tumor-infiltrating lymphocytes in laryngeal squamous
cell carcinoma. Clin Cancer Res. 22:704–713. 2016. View Article : Google Scholar
|
|
31
|
Taube JM, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL
and Chen L: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med. 4:pp.
127ra1372012, View Article : Google Scholar
|
|
32
|
Jiang X, Wang J, Deng X, Xiong F, Ge J,
Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor
microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol
Cancer. 18:102019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
LaCasse CJ, Janikashvili N, Larmonier CB,
Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M,
Bonnotte B, et al: Th-1 lymphocytes induce dendritic cell tumor
killing activity by an IFN-γ-dependent mechanism. J Immunol.
187:6310–6317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maraskovsky E, Chen W and Shortman K: IL-2
and IFN-gamma are two necessary lymphokines in the development of
cytolytic T cells. J Immunol. 143:1210–1214. 1989.PubMed/NCBI
|
|
35
|
Chen L, Tourvieille B, Burns GF, Bach FH,
Mathieu-Mahul D, Sasportes M and Bensussan A: Interferon: A
cytotoxic T lymphocyte differentiation signal. Eur J Immunol.
16:767–770. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiao M, Wang C, Zhang J, Li Z, Zhao X and
Qin Z: IFNgamma promotes papilloma development by up-regulating
Th17-associated inflammation. Cancer Res. 69:2010–2017. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsuda M, Nakamoto Y, Suzuki S, Kurata T
and Kaneko SJ: Interferon-gamma-mediated hepatocarcinogenesis in
mice treated with diethylnitrosamine. Lab Invest. 85:655–663. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hanada T, Kobayashi T, Chinen T, Saeki K,
Takaki H, Koga K, Minoda Y, Sanada T, Yoshioka T, Mimata H, et al:
IFNgamma-dependent, spontaneous development of colorectal
carcinomas in SOCS1-deficient mice. J Exp Med. 203:1391–1397. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alberts DS, Marth C, Alvarez RD, Johnson
G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH,
Clouser MC, et al: Randomized phase 3 trial of interferon gamma-1b
plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel
alone for first-line treatment of advanced ovarian and primary
peritoneal carcinomas: Results from a prospectively designed
analysis of progression-free survival. Gynecol Oncol. 109:174–181.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang W, Zhang J, Zhang Z, Guo Y, Wu Y,
Wang R, Wang L, Mao S and Yao X: Overexpression of indoleamine
2,3-dioxygenase 1 promotes epithelial-mesenchymal transition by
activation of the IL-6/STAT3/PD-L1 pathway in bladder cancer.
Transl Oncol. 12:485–492. 2019. View Article : Google Scholar
|
|
41
|
Decker T and Kovarik P: Serine
phosphorylation of STATs. Oncogene. 19:2628–2637. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Aziz MH, Manoharan HT, Church DR,
Dreckschmidt NE, Zhong W, Oberley TD, Wilding G and Verma AK:
Protein kinase Cepsilon interacts with signal transducers and
activators of transcription 3 (Stat3), phosphorylates Stat3Ser727,
and regulates its constitutive activation in prostate cancer.
Cancer Res. 67:8828–8838. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sakaguchi M, Oka M, Iwasaki T, Fukami Y
and Nishigori C: Role and regulation of STAT3 phosphorylation at
Ser727 in melanocytes and melanoma cells. J Invest Dermatol.
132:1877–1885. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gough DJ, Koetz L and Levy DE: The MEK-ERK
pathway is necessary for serine phosphorylation of mitochondrial
STAT3 and Ras-mediated transformation. PLoS One. 8:e833952013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Decker T and Kovarik P: Transcription
factor activity of STAT proteins: Structural requirements and
regulation by phosphorylation and interacting proteins. Cell Mol
Life Sci. 55:1535–1546. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fang Y, Zhong L, Lin M, Zhou X, Jing H,
Ying M, Luo P, Yang B and He Q: MEK/ERK dependent activation of
STAT1 mediates dasatinib-induced differentiation of acute myeloid
leukemia. PLoS One. 8:pp. e669152013, View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nitulescu II, Meyer SC, Wen QJ, Crispino
JD, Lemieux ME, Levine RL, Pelish HE and Shair MD: Mediator kinase
phosphorylation of STAT1 S727 promotes growth of neoplasms with
JAK-STAT activation. EBioMedicine. 26:112–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Goren I, Pfeilschifter J and Frank S:
Determination of leptin signaling pathways in human and murine
keratinocytes. Biochem Bioph Res Commun. 303:1080–1085. 2003.
View Article : Google Scholar
|
|
49
|
Kondo K, Shaim H, Thompson PA, Burger JA,
Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, et al:
Ibrutinib modulates the immunosuppressive CLL microenvironment
through STAT3-mediated suppression of regulatory B-cell function
and inhibition of the PD-1/PD-L1 pathway. Leukemia. 32:960–970.
2018. View Article : Google Scholar
|
|
50
|
Zhou L, Schandené L, Mordvinov VA,
Chatelain P, Pradier O, Goldman M and Stordeur P: Trapidil inhibits
monocyte CD40 expression by preventing IFN-γ-induced STAT1 S727
phosphorylation. Int Immunopharmacol. 4:863–871. 2004. View Article : Google Scholar : PubMed/NCBI
|
